EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Valsartan Reduces Myocardial Ischemia–Reperfusion Injury by Inhibiting Ferritinophagy‐Mediated Ferroptosis

Xumin Wang, Bixue Zhang iD, Xin Li, Qianqian Xu, Yuanliang Sun, Kaikai Zhao, Xintao Zhou, Yuhong Wu, Zheng Cheng

Journal of Cellular and Molecular Medicine · 2026-07 · 30 (13)

DOI: 10.1111/jcmm.71269 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 02.07.2026. Verfasst von Xumin Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Sixth Affiliated Hospital, Xinjiang Medical University, Urumqi, China. Hauptthemen laut MEDLINE: Ferroptosis, Valsartan, Myocardial Reperfusion Injury, Autophagy. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Key Research and Development Projects of Shaanxi Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Revascularisation is the key therapeutic strategy for acute myocardial infarction (AMI). However, the opening of the ‘culprit artery’ is accompanied by myocardial ischemia–reperfusion injury (IRI), partially offsetting the benefits of revascularisation. At present, effective methods to alleviate myocardial IRI are lacking. Cardiomyocyte ferritinophagy induces myocardial ferroptosis and IRI. In the present study, the RT‐PCR, western blotting, co‐immunoprecipitation, and immunofluorescence co‐localisation experiments revealed that hypoxia‐reoxygenation (H/R) of cardiomyocytes induces the dephosphorylation of Mst1 at Thr183, a crucial autophagy inhibitory site. Its dephosphorylation impairs the phosphorylation of Beclin1 at Ser295, thereby potentiating ferritinophagy, triggering ferroptosis and exacerbating H/R‐induced cardiomyocyte injury. In addition, valsartan restored the phosphorylation of Mst1 at Thr183 and Beclin1 at Ser295, thereby inhibiting myocardial ferritinophagy and ferroptosis. Valsartan also inhibits cardiomyocyte ferritinophagy by blocking the angiotensin II type 1 receptor. In vivo, valsartan ameliorated myocardial ferritinophagy, ferroptosis and IRI. However, following treatment with a ferroptosis inhibitor, valsartan failed to further alleviate myocardial IRI. In cardiomyocyte‐specific Mst1 knockout mice, valsartan failed to suppress myocardial ferritinophagy and ferroptosis, and consequently showed no therapeutic efficacy against IRI. Pre‐revascularisation administration of valsartan attenuated revascularisation‐induced myocardial injury and improved cardiac function in patients with AMI. These findings suggest that valsartan may mitigate myocardial IRI and improve clinical outcomes in patients with AMI by regulating the AT 1 R/Mst1/Beclin1 axis, thus inhibiting myocardial ferritinophagy and ferroptosis. Trial Registration The Chinese Clinical Trial Registry (TRN ChiCTR2100043501)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisValsartanMyocardial Reperfusion InjuryAutophagyAnimalsMyocytes, CardiacMiceMalePhosphorylationBeclin-1Proto-Oncogene ProteinsHumansDisease Models, Animal

Stichwörter der Autor:innen

Mst1ferritinophagyferroptosismyocardial ischemia–reperfusion injuryvalsartan

Substanzen

ValsartanBeclin-1Proto-Oncogene Proteins

Autor:innen und Institutionen

  • Department of Cardiology, Sixth Affiliated Hospital, Xinjiang Medical University, Urumqi, China.
  • Department of Otolaryngology, Sixth Affiliated Hospital, Xinjiang Medical University, Urumqi, China.
  • Department of Basic Medical Science Academy, Air Force Medical University, Xi'an, Shaanxi, China.
  • Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
  • Department of Cardiology, Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
  • Department of Cardiology, Second Affiliated Hospital, Harbin Medical University, Harbin, Heilongjiang, China.

ORCID-Profile: Bixue Zhang

Förderung

  • National Natural Science Foundation of China
  • China Postdoctoral Science Foundation
  • Key Research and Development Projects of Shaanxi Province
  • Xinjiang Tianchi Doctoral Project

Zitieren

APA

Wang, X., Zhang, B., Li, X., Xu, Q., Sun, Y., Zhao, K., Zhou, X., Wu, Y., & Cheng, Z. (2026). Valsartan Reduces Myocardial Ischemia–Reperfusion Injury by Inhibiting Ferritinophagy‐Mediated Ferroptosis. Journal of Cellular and Molecular Medicine, 30(13). https://doi.org/10.1111/jcmm.71269

Vancouver

Wang X, Zhang B, Li X, Xu Q, Sun Y, Zhao K, et al. Valsartan Reduces Myocardial Ischemia–Reperfusion Injury by Inhibiting Ferritinophagy‐Mediated Ferroptosis. Journal of Cellular and Molecular Medicine. 2026;30(13). doi:10.1111/jcmm.71269

BibTeX
@article{Wang2026,
  author = {Wang, Xumin and Zhang, Bixue and Li, Xin and Xu, Qianqian and Sun, Yuanliang and Zhao, Kaikai and Zhou, Xintao and Wu, Yuhong and Cheng, Zheng},
  title = {Valsartan Reduces Myocardial Ischemia–Reperfusion Injury by Inhibiting Ferritinophagy‐Mediated Ferroptosis},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2026},
  volume = {30},
  number = {13},
  doi = {10.1111/jcmm.71269}
}
Kostenlos starten →